HIV缓解试验中短期分析性治疗中断的中枢神经系统安全性观察
该观察性研究纳入30例急性HIV感染后启动ART的参与者,在4项ATI缓解试验中评估中枢神经系统安全性。ATI中位持续35天,结果显示情绪与神经系统检查无差异、认知轻度改善,但基底节胆碱MRS轻度恶化,提示需进一步评估更高重启阈值与更长ATI的安全性。
要点
- 短期密切监测的ATI未观察到不良中枢神经系统事件。
- ATI后基底节总胆碱MRS轻度恶化,提示神经元膜改变。
- 血浆病毒血症时部分参与者脑脊液可检出低水平HIV-1 RNA。
核心结论
- 在急性治疗HIV感染者中,短期密切监测的ATI未观察到不良中枢神经系统效应,但基底节胆碱MRS出现改变。
研究设计与样本
- 观察性研究,30例急性HIV感染后启动ART的参与者,跨4项ATI缓解试验进行中枢神经系统评估。
主要发现
- ATI后中位情绪评分与神经系统检查无差异,认知表现轻度改善。
- ATI期间20例有血浆病毒血症的参与者中6例脑脊液可检出低水平HIV-1 RNA。
- 脑脊液免疫激活标志物与脑DTI指标无组间变化。
- ATI后基底节总胆碱MRS轻度恶化,提示神经元膜改变。
关键数值与推荐
- 参与者中位年龄30岁,29/30为男性。
- ATI前中位ART时间3年,ATI中位持续35天。
- 血浆病毒载量>1000 copies/mL时恢复ART。
临床怎么用
- 短期密切监测的ATI在急性治疗HIV感染者中未显示不良中枢神经系统效应。
- 需进一步评估更高ART重启阈值与更长ATI持续时间的中枢神经系统安全性。
局限性
- 样本量较小(30例),且绝大多数为男性。
- 脑脊液采样为选择性进行,仅20例有血浆病毒血症者中部分可评估。
- ATI持续时间较短(中位35天),结论外推受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The central nervous system (CNS) is a likely reservoir of human immunodeficiency virus (HIV), vulnerable to viral rebound, inflammation, and clinical changes upon stopping antiretroviral therapy (ART). It is critical to evaluate the CNS safety of studies using analytic treatment interruption (ATI) to assess HIV remission. METHODS: Thirty participants who started ART during acute HIV infection underwent CNS assessments across 4 ATI remission trials. ART resumption occurred with plasma viral load >1000 copies/mL. CNS measures included paired pre- vs post-ATI measures of mood, cognitive performance, and neurologic examination, with elective cerebrospinal fluid (CSF) sampling, brain diffusion tensor imaging (DTI) and magnetic resonance spectroscopy (MRS). RESULTS: Median participant age was 30 years old and 29/30 were male. Participants' median time on ART before ATI was 3 years, and ATI lasted a median of 35 days. Post-ATI, there were no differences in median mood scores or neurologic findings and cognitive performance improved modestly. During ATI, a low level of CSF HIV-1 RNA was detectable in 6 of 20 participants with plasma viremia, with no group changes in CSF immune activation markers or brain DTI measures. Mild worsening was identified in post-ATI basal ganglia total choline MRS, suggesting an alteration in neuronal membranes. CONCLUSION: No adverse CNS effects were observed with brief, closely monitored ATI in participants with acutely treated HIV, except an MRS alteration in basal ganglia choline. Further studies are needed to assess CNS ATI safety in HIV remission trials, particularly for studies using higher thresholds to restart ART and longer ATI durations.
引用
- Hellmuth J, Muccini C, Colby DJ, et al. Central Nervous System Safety During Brief Analytic Treatment Interruption of Antiretroviral Therapy Within 4 Human Immunodeficiency Virus Remission Trials: An Observational Study in Acutely Treated People Living With Human Immunodeficiency Virus. Clin Infect Dis. 2021. PMID: 32916708. doi:10.1093/cid/ciaa1344
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。